Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes

Gerjan De Bruin, Eva M. Huber, Bo Tao Xin, Eva J. Van Rooden, Karol Al-Ayed, Kyung Bo Kim, Alexei F. Kisselev, Christoph Driessen, Mario Van Der Stelt, Gijsbert A. Van Der Marel, Michael Groll, Herman S. Overkleeft

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


Mammalian genomes encode seven catalytic proteasome subunits, namely, β1c, β2c, β5c (assembled into constitutive 20S proteasome core particles), β1i, β2i, β5i (incorporated into immunoproteasomes), and the thymoproteasome-specific subunit β5t. Extensive research in the past decades has yielded numerous potent proteasome inhibitors including compounds currently used in the clinic to treat multiple myeloma and mantle cell lymphoma. Proteasome inhibitors that selectively target combinations of β1c/β1i, β2c/β2i, or β5c/β5i are available, yet ligands truly selective for a single proteasome activity are scarce. In this work we report the development of cell-permeable β1i and β5i selective inhibitors that outperform existing leads in terms of selectivity and/or potency. These compounds are the result of a rational design strategy using known inhibitors as starting points and introducing structural features according to the X-ray structures of the murine constitutive and immunoproteasome 20S core particles.

Original languageEnglish
Pages (from-to)6197-6209
Number of pages13
JournalJournal of Medicinal Chemistry
Issue number14
StatePublished - Jul 24 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes'. Together they form a unique fingerprint.

Cite this